Fresenius Medical Care (NYSE:FMS) Coverage Initiated at Berenberg Bank

Investment analysts at Berenberg Bank started coverage on shares of Fresenius Medical Care (NYSE:FMS - Get Free Report) in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $25.60 price target on the stock. Berenberg Bank's target price suggests a potential upside of 21.38% from the stock's current price.

Other equities research analysts have also recently issued reports about the stock. StockNews.com started coverage on shares of Fresenius Medical Care in a report on Friday, November 1st. They issued a "strong-buy" rating on the stock. Truist Financial raised their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the company a "hold" rating in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.30.

Fresenius Medical Care Stock Up 3.7 %

Shares of NYSE:FMS traded up $0.76 during midday trading on Wednesday, hitting $21.09. The stock had a trading volume of 398,755 shares, compared to its average volume of 370,813. The company has a market cap of $12.38 billion, a P/E ratio of 21.74, a PEG ratio of 0.96 and a beta of 0.91. Fresenius Medical Care has a 12 month low of $16.66 and a 12 month high of $22.76. The business's 50-day simple moving average is $20.38 and its 200-day simple moving average is $20.21. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45.

Institutional Trading of Fresenius Medical Care

Several institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP lifted its holdings in shares of Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company's stock worth $36,000 after buying an additional 581 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company's stock worth $278,000 after purchasing an additional 624 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company's stock worth $166,000 after purchasing an additional 672 shares during the period. Ritholtz Wealth Management raised its position in shares of Fresenius Medical Care by 2.5% in the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company's stock valued at $704,000 after buying an additional 895 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Fresenius Medical Care by 6.7% in the second quarter. Rhumbline Advisers now owns 18,067 shares of the company's stock valued at $345,000 after buying an additional 1,128 shares during the period. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.